Stockscreener 앱 받기
70.93
0.15%
-0.11
전일 마감가:
$71.04
열려 있는:
$71.12
하루 거래량:
452.56K
Relative Volume:
0.74
시가총액:
$2.68B
수익:
-
순이익/손실:
$-91.00M
주가수익비율:
-19.33
EPS:
-3.67
순현금흐름:
$-74.38M
1주 성능:
-9.23%
1개월 성능:
-22.46%
6개월 성능:
+23.70%
1년 성능:
+18.32%
1일 변동 폭
$70.31
$73.07
1주일 범위
$70.31
$79.69
52주 변동 폭
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
IRON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
70.93 | 2.68B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-11 | 재개 | Raymond James | Strong Buy |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Asianet Newsable
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com Canada
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Morgan Stanley Reaffirms Positive Outlook on IRON Despite FDA Re - GuruFocus
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨 - XTB.com
Disc Medicine (IRON) Shares Decline as FDA Review Faces Brief De - GuruFocus
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents - marketscreener.com
How Disc Medicine’s New HR Chief and Bitopertin Review Could Shape IRON’s Commercial Readiness - Sahm
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Gainers: Should I hold or sell Disc Medicine Inc stock in 2025July 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - Bộ Nội Vụ
Is Disc Medicine (IRON) Offering An Opportunity After Recent Volatility And DCF Valuation Gap - Yahoo Finance
Disc Medicine appoints Lisa Amaya Price as chief human resources officer - Investing.com Nigeria
Disc Medicine outlines 2026 pipeline priorities after NDA submission By Investing.com - Investing.com Nigeria
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - citybiz
Disc Medicine (IRON) Appoints New Chief Human Resources Officer - GuruFocus
Disc Medicine appoints Lisa Amaya Price as chief human resources officer By Investing.com - Investing.com India
News | decaturdailydemocrat.comDisc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - FinancialContent
Disc Medicine (IRON) Shares Strategic Goals and Pipeline Developments for 2026 - GuruFocus
Disc Medicine outlines 2026 pipeline priorities after NDA submission - Investing.com
Disc Medicine prepares for potential 2026 bitopertin FDA decision - TipRanks
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 - The Manila Times
FDA weighs new blood disorder drug as small biotech sets a pivotal 2026 - Stock Titan
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Disc Medicine advances bitopertin in FDA pilot program - MSN
Aug Intraday: How supply chain issues affect Disc Medicine Inc. stockPrice Action & Daily Profit Focused Stock Screening - Улправда
Will Disc Medicine Inc. stock deliver strong dividend growthWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
A Look At Disc Medicine (IRON) Valuation After Bitopertin NDA Filing And Positive DISC-0974 Phase 2 Data - Sahm
How institutional buying supports Disc Medicine Inc. stockJuly 2025 Technicals & Technical Entry and Exit Tips - Улправда
How supply chain issues affect Disc Medicine Inc. stockWeekly Trading Summary & Intraday High Probability Setup Alerts - Улправда
Aug Selloffs: Why Disc Medicine Inc. stock is favored by top institutionsJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - Улправда
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy - MSN
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech targeting serious blood diseases to speak at J.P. Morgan - Stock Titan
Why Disc Medicine Inc. stock is seen as undervalued2026 world cup usa national team round of 16 young talents transition play winner prediction tactical review - Улправда
Disc Medicine, Inc. (IRON) Stock Analysis: Strong Buy Ratings and a Promising 54.73% Potential Upside - DirectorsTalk Interviews
Disc Medicine’s Cash Runway And NDA Milestones Could Be A Game Changer For IRON - Sahm
Disc Medicine (NASDAQ:IRON) Insider Sells $511,485.00 in Stock - MarketBeat
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Disc Medicine Inc 주식 (IRON) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Sale |
78.69 |
6,500 |
511,472 |
37,793 |
4.73%
0.92%
자본화:
|
볼륨(24시간):